Cayman LCK Inhibitor

Lymphocyte-specific protein tyrosine kinase (LCK) is a member of the Src-family of non-receptor protein tyrosine kinases and plays a critical role in the initial steps of T cell receptor signaling that trigger the production of cytokines.¹ LCK inhibitor is a pyrrolopyrimidine that blocks the activity of two forms of LCK kinase, LCK (64-509) and LCKCD, with IC₅₀ values of <1 and 2 nM, respectively.^2,3 It inhibits the related kinases Src, Kdr, and Tie-2 with much weaker potency (IC₅₀s = 70 nM, 1.57, and 1.98 µM, respectively) and only minimally inhibits the activities of EGFR, PKC, CDC2/B and ZAP-70 (IC₅₀s = 3.2, >33, >50, and >50 µM, respectively).^2,3 This compound has been shown to inhibit T cell receptor-stimulated IL-2 production in mice (ED₅₀s = 4 and 25 mg/kg when administered either i.p. or orally).^2,4

WARNING This product is not for human or veterinary use.